Literature DB >> 20484028

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Isabel Poschke1, Dimitrios Mougiakakos, Johan Hansson, Giuseppe V Masucci, Rolf Kiessling.   

Abstract

Myeloid-derived suppressor cells (MDSC) have emerged as key immune modulators in various tumor models and human malignancies, but their characteristics in humans remain to be unequivocally defined. In this study, we have examined circulating CD14(+)HLA-DR(-/low) MDSC in 34 advanced malignant melanoma (MM) patients. Their frequency is significantly increased and associated with disease activity. Contrary to the common notion that MDSC are a heterogeneous population of exclusively immature cells, we find the coexpression of markers associated with mature phenotype. We show for the first time the overexpression of CD80, CD83, and DC-Sign in human MDSC. Further, increased levels of signal transducer and activator of transcription 3 (Stat3), an important regulator in MDSC development and function, were noted in MM-MDSC. Stat3 was altered toward an active, phosphorylated state in the HLA-DR(-) population of CD14(+) cells and was more reactive to activating stimuli in patients. Importantly, inhibition of Stat3 abolished their suppressive activity almost completely. The described MM-MDSC use arginase in conjunction with other yet undefined mechanisms to suppress CD4(+) and CD8(+) T cells. Several observations suggest a redox imbalance in MDSC and indicate an important role of Stat3-dependent oxidative stress in MDSC-mediated T-cell suppression. These results emphasize the diversity of MDSC in human cancer and provide potential targets for therapeutic interventions. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484028     DOI: 10.1158/0008-5472.CAN-09-3767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  183 in total

1.  Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.

Authors:  Baisakhi Raychaudhuri; Patricia Rayman; Joanna Ireland; Jennifer Ko; Brian Rini; Ernest C Borden; Jorge Garcia; Michael A Vogelbaum; James Finke
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

3.  Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species.

Authors:  Robert S Tacke; Hai-Chon Lee; Celeste Goh; Jeremy Courtney; Stephen J Polyak; Hugo R Rosen; Young S Hahn
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

4.  PD-1 Blockade Expands Intratumoral Memory T Cells.

Authors:  Antoni Ribas; Daniel Sanghoon Shin; Jesse Zaretsky; Juliet Frederiksen; Andrew Cornish; Earl Avramis; Elizabeth Seja; Christine Kivork; Janet Siebert; Paula Kaplan-Lefko; Xiaoyan Wang; Bartosz Chmielowski; John A Glaspy; Paul C Tumeh; Thinle Chodon; Dana Pe'er; Begoña Comin-Anduix
Journal:  Cancer Immunol Res       Date:  2016-01-19       Impact factor: 11.151

5.  Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Authors:  Jeffrey Weber; Geoffrey Gibney; Ragini Kudchadkar; Bin Yu; Pingyan Cheng; Alberto J Martinez; Jodie Kroeger; Allison Richards; Lori McCormick; Valerie Moberg; Heather Cronin; Xiuhua Zhao; Michael Schell; Yian Ann Chen
Journal:  Cancer Immunol Res       Date:  2016-02-12       Impact factor: 11.151

6.  HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.

Authors:  Ankita Garg; Stephen A Spector
Journal:  J Infect Dis       Date:  2013-09-01       Impact factor: 5.226

7.  Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.

Authors:  Rahul Chavan; Daniela Salvador; Michael P Gustafson; Allan B Dietz; Wendy Nevala; Svetomir N Markovic
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

8.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

9.  Expansion of myeloid-derived suppressor cells promotes differentiation of regulatory T cells in HIV-1+ individuals.

Authors:  Ling Wang; Juan Zhao; Jun P Ren; Xiao Y Wu; Zheng D Morrison; Mohamed A Elgazzar; Shun B Ning; Jonathan P Moorman; Zhi Q Yao
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

10.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.